Literature DB >> 18237729

Mu-opioid receptor heterooligomer formation with the dopamine D1 receptor as directly visualized in living cells.

Jason R Juhasz1, Ahmed Hasbi, Asim J Rashid, Christopher H So, Susan R George, Brian F O'Dowd.   

Abstract

Our immunohistochemistry experiments demonstrated that the mu-opioid receptor co-localized with the dopamine D1 receptor in neurons of the cortex and caudate nucleus. On the basis of this physiological data we further investigated whether these two G protein coupled receptors formed hetero-oligomers in living cells. To demonstrate hetero-oligomerization we used a novel strategy, the method used harnessed the physiological cellular mechanism for transport of proteins to the nucleus. The nuclear translocation pathway was adapted for the visualization of mu-opioid hetero-oligomers with the dopamine D1 receptor. The receptor hetero-oligomer complex formed resulted in a significantly enhanced surface expression of mu-opioid receptor. This hetero-oligomer formation involved the interaction of mu-opioid receptor with the dopamine D1 receptor carboxyl tail, since a dopamine D1 receptor substituted with the carboxyl of the dopamine D5 receptor failed to increase surface expression of mu-opioid receptor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18237729     DOI: 10.1016/j.ejphar.2007.11.060

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  23 in total

Review 1.  Pharmacology of signaling induced by dopamine D(1)-like receptor activation.

Authors:  Ashiwel S Undieh
Journal:  Pharmacol Ther       Date:  2010-06-12       Impact factor: 12.310

Review 2.  Membrane functional organisation and dynamic of mu-opioid receptors.

Authors:  André Lopez; Laurence Salomé
Journal:  Cell Mol Life Sci       Date:  2009-03-20       Impact factor: 9.261

Review 3.  In vivo opioid receptor heteromerization: where do we stand?

Authors:  D Massotte
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

4.  Co-localization of mu-opioid and dopamine D1 receptors in the medial preoptic area and bed nucleus of the stria terminalis across seasonal states in male European starlings.

Authors:  Jeremy A Spool; Devin P Merullo; Changjiu Zhao; Lauren V Riters
Journal:  Horm Behav       Date:  2018-11-20       Impact factor: 3.587

5.  D1-mGlu5 heteromers mediate noncanonical dopamine signaling in Parkinson's disease.

Authors:  Irene Sebastianutto; Elise Goyet; Laura Andreoli; Joan Font-Ingles; David Moreno-Delgado; Nathalie Bouquier; Céline Jahannault-Talignani; Enora Moutin; Luisa Di Menna; Natallia Maslava; Jean-Philippe Pin; Laurent Fagni; Ferdinando Nicoletti; Fabrice Ango; M Angela Cenci; Julie Perroy
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

6.  A dopamine D1 receptor-dependent β-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice.

Authors:  Nikhil M Urs; Tanya L Daigle; Marc G Caron
Journal:  Neuropsychopharmacology       Date:  2010-10-27       Impact factor: 7.853

7.  Dopamine D1 receptor antagonism in the prelimbic cortex blocks the reinstatement of heroin-seeking in an animal model of relapse.

Authors:  Ronald E See
Journal:  Int J Neuropsychopharmacol       Date:  2009-02-23       Impact factor: 5.176

Review 8.  Gestational overgrowth and undergrowth affect neurodevelopment: similarities and differences from behavior to epigenetics.

Authors:  Nicola M Grissom; Teresa M Reyes
Journal:  Int J Dev Neurosci       Date:  2012-11-28       Impact factor: 2.457

9.  Cocaine withdrawal-induced trafficking of delta-opioid receptors in rat nucleus accumbens.

Authors:  Lisa M Ambrose-Lanci; Niluk B Peiris; Ellen M Unterwald; Elisabeth J Van Bockstaele
Journal:  Brain Res       Date:  2008-03-15       Impact factor: 3.252

10.  Modulation of appetitive motivation by prefrontal cortical mu-opioid receptors is dependent upon local dopamine D1 receptor signaling.

Authors:  Ryan A Selleck; Juliana Giacomini; Brandon D Buchholtz; Curtis Lake; Ken Sadeghian; Brian A Baldo
Journal:  Neuropharmacology       Date:  2018-08-04       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.